Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study

George Bakris, Pablo E Pergola, Belkis Delgado, Diyan Genov, Tamar Doliashvili, Nam Vo, Y Fred Yang, James McCabe, Vincent Benn, Bertram Pitt, BLOCK-CKD Study Group, George Bakris, Pablo E Pergola, Belkis Delgado, Diyan Genov, Tamar Doliashvili, Nam Vo, Y Fred Yang, James McCabe, Vincent Benn, Bertram Pitt, BLOCK-CKD Study Group

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT03574363.

Keywords: blood pressure; hyperkalemia; hypertension; kidney; mineralocorticoid receptor antagonist.

Figures

Figure 1.
Figure 1.
The effect of KBP-5074 on blood pressure in CKD cohort.A) Systolic blood pressure (SBP) from baseline to end of treatment (intent-to-treat [ITT] population/last observation carried forward [LOCF], N=162). P values were calculated based on ANCOVA model. B, Diastolic blood pressure (DBP) from baseline to end of treatment (ITT population/LOCF, N=162).
Figure 2.
Figure 2.
Line plot of potassium over time (safety population). On average, increases in potassium by day 84 were 0.08, 0.19, and 0.33 mmol/L in the placebo, 0.25 mg, and 0.5 mg groups, respectively.

References

    1. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al. ; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53–e90. doi: 10.1161/HYP.0000000000000084
    1. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34:333–339. doi: 10.1016/j.semnephrol.2014.04.008
    1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34:1803–1805. doi: 10.1093/ndt/gfz174
    1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv J, Garg AX, Knight J, et al. . Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–1982. doi: 10.1016/S0140-6736(14)61601-9
    1. CDC Chronic Kidney Disease Surveillance System—United States. Prevalence of CKD in the general population: CKD stages among US adults, 1988-1994 vs. 1999-2006 vs. 2007-2014 vs. 2015-2016. Accessed January 14, 2021.
    1. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98–105. doi: 10.1136/heartjnl-2018-313599
    1. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62:201–213. doi: 10.1053/j.ajkd.2013.03.018
    1. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, et al. SPRINT Research Group. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812–2823. doi: 10.1681/A.S.N.2017020148
    1. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, et al. ; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–2068. doi: 10.1016/S0140-6736(15)00257-3
    1. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540–1550. doi: 10.1016/S0140-6736(19)32135-X
    1. Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bushinsky DA. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46:213–221. doi: 10.1159/000479802
    1. Inspra. Prescribing information. 2020. Pfizer. Accessed January 16, 2021.
    1. Aldactone. Prescribing information. 2020. Pfizer. Accessed January 16, 2021.
    1. Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33:542–551. doi: 10.1038/s41371-019-0207-x
    1. Nakamura T, Kawaguchi A. Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10:353–365. doi: 10.1002/cpdd.855
    1. Bakris G, Yang YF, Pitt B. Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial. Hypertension. 2020;76:144–149. doi: 10.1161/HYPERTENSIONAHA.120.15199
    1. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, et al. ; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–2229. doi: 10.1056/NEJMoa2025845
    1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–3104. doi: 10.1093/eurheartj/ehy339
    1. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and nonsteroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152–161. doi: 10.1093/eurheartj/ehaa736

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel